_______________________________________________ Psychedelic Medicine and Interventional Psychiatry
MAJOR PSYCHEDELIC RESEARCH CENTERS IN THE UNITED STATES
Johns Hopkins Center for Psychedelic and Consciousness Research https://hopkinspsychedelic.org National Institutes of Health Funding https://pubmed.ncbi.nlm.nih.gov/34624734 Yale University https://medicine.yale.edu/psychiatry/education/residency/interest/psychedelic_science_group Mount Sinai https://www.mountsinai.org/about/newsroom/2021/mount-sinai-health-system-launches-center-for-psychedelic-research Stanford University
https://med.stanford.edu/spsg.html University of California, San Francisco https://neuroscape.ucsf.edu/psychedelics Duke University
https://dukepsychedelics.org University of Texas at Austin https://dellmed.utexas.edu/units/center-for-psychedelic-research-and-therapy Washington University in St. Louis (WUSTL) https://healthymind.wustl.edu/items/washington-universitys-program-in-psychedelic-research Harvard/Massachusetts General Hospital https://www.massgeneral.org/psychiatry/treatments-and-services/center-for-the-neuroscience-of-psychedelics
Source: Compiled by Author
Table 4
compared with 60% of those who received 10-mg psilocybin and 6.9% of those who received placebo. The second most common treatment-emergent adverse event was illusion, which was experienced by 60% of subjects receiving 25-mg psilocy- bin and 63.3% of those receiving 10-mg psilocybin; 13.8% of those receiving placebo reported experiencing this effect. Other treatment-emergent adverse events reported more com- monly among the treatment groups included mood alteration, headache, fatigue, and euphoric mood, all of which were lower or altogether non-existent in the placebo group. Also absent in the placebo group were auditory and tactile hallucinations [39]. The researchers concluded [39]: This study demonstrated the feasibility of one-to- one psychological support from specially trained therapists during [the] simultaneous administra- tion of psilocybin in a supervised clinical setting in healthy volunteers. A single dose of psilocybin 10 mg or 25 mg elicited no serious adverse effects and did not appear to produce any clinically relevant det- rimental short- or long-term effects, compared with placebo, in cognitive or social functioning or emo- tional regulation in this study in health volunteers.
In studies using psilocybin, the most common adverse reac- tions were found to be headache, nausea, and hypertension, and events were considered to be equivalent to those found with the use of SSRIs [40]. However, it should also be noted that the subjects in psilocybin clinical trials are usually screened for a family history of schizophrenia, major depression with psychotic features, high risk for suicide, and severe personality disorders before inclusion [40]. Another study at Johns Hopkins evaluated the efficacy and safety of psilocybin for the treatment of major depressive disorder. In this randomized study, 24 patients 21 to 75 years of age with moderate-to-severe unipolar depression were randomized to either immediate or delayed treatment. Subjects were administered two doses of psilocybin along with supportive psychotherapy. Researchers found a greater than 50% reduction in depressive symptoms, as measured by the GRID-Hamilton Depression Rating Scale (GRID-HAMD), in the treatment group. Before initiating psilocybin therapy, subjects first received six to eight hours of preparation with trained facilitators. The psilocybin was administered at doses of 20 mg/70 kg and 30 mg/70 kg, about two weeks apart, while subjects were in a comfortable room supervised by two
99
EliteLearning.com/Social-Work
Powered by FlippingBook